Inhibitor of NF-κB transcriptional activator and uses thereof

ABSTRACT

Compositions involving IκB (i.e., inhibitor of Nuclear Factor-κB or NF-κB) and methods of using the same are described that have applications for the identification of prophylactics or therapeutics for the treatment of diseases resulting from altered gene expression, including genes that encode cytokines or related molecules.

The present application is a division of U.S. patent application Ser.No. 08/119,891, filed Sep. 10, 1993, now abandoned, which is acontinuation of U.S. patent application Ser. No. 07/702,770, filed May17, 1991, now abandoned.

FIELD OF THE INVENTION

This invention is in the field of molecular biology/biochemistry.Described herein are compositions that have applications for theidentification of prophylactics or therapeutics preferably for thetreatment of viral diseases or diseases resulting from the undesirableproduction of cytokines or antibody. More specifically, an inhibitorymaterial is shown that effects the transcriptional activity of genesthat encode various proteins, including genes that encode cytokines orrelated molecules, viral proteins and imrnunoglobulin.

BACKGROUND OF THE INVENTION

Cytokines are small molecular weight proteins that have a myriad ofbiological functions (for background information, see Balkwill, F. R.,et al., 1989, Immun. Today, 10:299). For example, cytokines are known tobe capable of stimulating their own synthesis, as well as the productionof other cytokines from a variety of cell types. They are alsoassociated with disease. A good example is the presence of the cytokinesinterleukin-1 (IL-1) and tumor necrosis factor (TNF). IL-1 has beendemonstrated to have multiple biological activities with the twoprominent being fever production and lymphocyte activation. Moreover,both cytokines, alone or in combination, cause a shock state in animalsthat hemodynamically and hematologically is characteristic of septicshock in man caused by bacterial infection. TNF, in addition, hasrecently been shown to be involved in initiating the expression of humanimmunodeficiency virus in human cells that carry latent virus. Folks etal., 1989, PNAS (USA), 86:2365. TNF and IL-1 also play a role in variousautoimmune diseases, particularly arthritis. Duff, et al. 1987,International Conference on Tumor Necrosis Factor and RelatedCytotoxins, 175:10.

In addition to IL-1 and TNF, another cytokine, IL-6, has recently beenshown to be involved in infection, particularly sepsis, as well as inaffecting the growth of tumor cells. Hack, et al., 1989, Blood, 74:1704,and Miki et al, 1989, FEB, 250:607. IL-6 is also termed hybridoma growthfactor, interferon-beta-2, B-cell stimulatory factor 2, 26 kD protein,and hepatocyte stimulating factor.

Adherence to an appropriate substratum has been shown to be important intranscriptional expression of cytokine mediators of inflammationproduced by macrophages or monocytes, and adherence to differentmatrices has recently been shown to result in preferential geneinduction (Sporn, S. A., et al., 1990, J. of Immun., 144:4434-4441;Thorens, B., et al., 1987, Cell, 48:671). For example, within 30 minutesof monocyte adherence to plastic, a complex set of regulatory events isinitiated as defined by rapid changes of mRNA levels of severalinflammatory mediators and proto-oncogenes (Haskill, S., et al., 1988,J. of Immunol., 140:1690). IL-1β,TNF-α and c-fos are rapidly elevated,whereas CSF-1 steady state mRNA levels increase by 90 minutes. Incontrast, expression of c-fms and lysozyme is rapidly down-regulatedThese genes are modulated by adherence to different biologicallyrelevant substrates (Eierman, D. F., 1989, J. of Immunol.,14:1970-1970).

Although high steady state mRNA levels of important mediators ofinflammation are rapidly induced by adherence, adherence by itself isinsufficient to cause efficient translation and secretion ofIL-1β,TNF-α, or CSF-1 (Haskill, S., et al., supra). Activation by asecond signal, such as bacterial endotoxin, is required for thesecretion of all three gene products. Thus, it is clear that signalsderived from the act of adherence are likely to play a significant rolein the activation and differentiation of monocytes allowing them torespond to infection and to influence the local tissue environment(Sporn, S. A, supra).

Recently, a protein termed NF-κB has been shown to be a transcriptionalactivator (Sen, R. and Baltimore, D., 1986, Cell, 4:705-716). Thisfactor has been shown to bind to DNA regulatory regions of certaincytokine genes (Leonardo, M. and Baltimore, D., 1989, Cell, 58:227-229).Various agents cause the induction of nuclear NF-κB DNA-binding activity(Sen and Baltimore, supra). It is thus thought that NF-κB is atranscriptional regulator of gene expression for various cytokine genes.It would therefore be desirable to identify molecules that inhibit theeffects of NF-κB since these would be useful to regulate the effects ofcytokines in the inflammatory response.

It has recently been shown that NF-κB is associated with a 36 kD proteintermed IκB (Baeurle, P. and Baltimore, D., 1988, Cell, 51:211-217;Baeurle, P. and Baltimore, D., 1988, Science, 242:540-546). NF-κBconsists of proteins having molecular weights of 50 and 65 kD. IκB bindsto the 65 kD subunit (Baeurle, P. and Baltimore, D., 1989, Genes andDevelopment, 3:1689-1698). Finally, recent experimental evidence showsthat phosphorylation of IκB blocks its inhibitory effect on DNA bindingactivity of NF-κB. This is consistent with the observation that proteinkinases activate NF-κB DNA binding activity in vitro (Ghosh, S. andBaltimore, D., 1990, Nature, 344:678-682).

Because of the importance of IκB in regulating gene expression, it willbe appreciated that the purification, cloning, and expression of thismolecule will make available assays for identification of regulators ofNF-κB and IκB that will have significant medical applications.

SUMMARY OF THE INVENTION

One aspect of the invention described herein consists of a descriptionof a protein that inhibits transcriptional activation by NF-κB that hasan approximate molecular weight of 34-38 kD.

A second aspect of the invention is the description of a cDNA sequencethat encodes a protein that inhibits transcriptional activation by NF-κBthat has an approximate molecular weight of 3436 kD.

A third aspect of the invention is a description of methods for cloningand expressing a 34 kD transcriptional activation inhibitor.

A fourth aspect of the invention is a method for identifying medicamentsusing IκB that are useful for controlling diseases resulting fromundesirable gene expression.

A fifth aspect of the invention is a method for identifying medicamentsthat enhance immune responses by their ability to block the effects ofIκB.

A sixth aspect of the invention is the identification of transcriptionalactivator inhibitors having properties similar to the instantlydescribed IκB, and methods of using such inhibitors to identifymedicaments that would be useful to treat diseases resulting fromundesirable gene expression.

A seventh aspect of the invention is a description of diagnosticprocedures for detecting diseases as a function of IκB expression.

These and other aspects of the invention will become more fullyappreciated upon a complete consideration of the invention describedbelow.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the cDNA sequence of MAD-3 (SEQ ID NO:16).

FIG. 2 shows the cDNA sequence of IκB (SEQ ID NO:17) and the deducedprotein sequence based thereon (SEQ ID NO:18). The 1.6 kb size of theclone is close to that predicted from the transcript size on Northernanalysis. The consensus tyrosine phosphorylation site and the possiblePI-3 kinase binding domain is underlined, the predicted PKCphosphorylation site is overlined and the thee ATTTA (SEQ ID NO: 1)motifs are underlined and typed in bold The ankyrin repeat domain (Luxet al., 1990, Nature, 144:36-42) is typed in bold.

FIG. 3 shows a Kyte-Doolittle hydrophilicity/hydrophobicity plot. Thefive ankyrin repeats are overlined and each repeat is marked. Thepredicted PI-3 kinase binding domain and the putative PKC kinase targetsequences are also overlined.

FIG. 4A shows in vitro transcribed IκB mRNA translates a 36-38 kDprotein with properties of IκB. 10% SDS polyacrylamide gel analyzingreticulocyte lysates programmed with in vitro transcribed lκB mRNA (lane1, WT) or with IκB mRNA transcribed from an AccI digested plasmid (lane2, Δ). Protein was labelled with ³⁵ S-methionine. The mobilities ofprestained molecular weight markers are shown.

FIG. 4B shows gel mobility shift analyzing programmed reticulocytelysates and nuclear extracts of PMA and PHA treated Jurkat T-cells. Forall lanes the Class I MHC enhancer probe was used. The following proteinsources were used: nuclear extracts of stimulated Jurkat T-cells (lane1), Jurkat extracts plus IκB programmed lysates (lane 2, WT), Jurkatextracts plus lysates translated with mRNA from the AccI-deletedconstruct (lane 3, Δ), Jurkat extracts plus mock translated reticulocytelysates alone (lane 5, MT). The large arrow indicates the mobility ofthe NF-κB/DNA complex and the small arrow indicates the mobility of theKBF1/DNA complex.

FIG. 4C shows gel mobility shift assay characterizing the nuclearextracts of the stimulated Jurkat T-cells. The following protein sourceswere used: extracts of stimulated Jurkat T-cells (lanes 1-5), pluseither antiserum to the p50 DNA-binding subunit of NF-κB (lane 4, 1indicates immune antiserum) or pre-immune (P) serum (lane 5). The DNAprobes are as indicated above the figure: MUT (MHC double point mutantprobe), Igκ (immunoglolublin kappa), and MHC (Class I MHC enhancerprobe). The large arrow indicates the mobility of the NF-κB/DNA complexand the small arrow indicates the mobility of the KBF1/DNA complex.

FIG. 5A shows specificity of inhibition of DNA-binding activity by theIκB protein. Gel mobility shift analyzing vaious DNA-binding activities.The adenovirus MLTF and Oct-1 (OCTA) probes (as indicated) wereincubated with nuclear extracts of stimulated Jurkat T-cells (lanes 1-3)plus IκB programmed lysates (lane 2, WT), or plus mock translatedlysates (ane 3, MT). The Class I MHC enhancer probe was incubated with aphosphocellulose fraction from HeLa cells (lane 1) containing theDNA-binding activity H2TF1 (Baldwin and Sharp, 1987, Mol. Cell. Biol.,7:305-313), plus IκB programmed lysates (lane 2, WT) or plus mocktranslated lysates (lane 3, MT).

FIG. 5B shows gel mobility shift analyzing NF-κB in nuclear extracts ofmonocytes. The Class I MHC enhancer probe was incubated with nuclearextracts of freshly isolated monocytes (lane 1). Lane 2 included theaddition of mock translated lysates (MT) and lane 3 included theaddition of IκB translated lysates (WT). The large arrow indicates themobility of the NF-κB/DNA complex and the small arrow indicates themobility of the KBF1/DNA complex.

FIG. 6 shows deoxycholate releases NF-κB DNA-binding activity from theIκb inhibition. Gel mobility shift using the Class I MHC enhancer probewith the following binding conditions: DNA-affinty purified NF-κB (lanes1-3), plus IκB programmed lysates (lanes 2 and 3). Following incubationof the purified NF-κB with the IκB programmed extract, DOC was addedfollowed by NP40 (lane 3). The arrow indicates the mobility of theNF-κB/DNA complex.

FIG. 7A shows kinetics of induction, substrate specificity, and tissuedistribution of IκB mRNA expression. Monocytes isolated by non-adherenttechniques were plated on Type IV collagen coated plates and RNA wasextracted from adherent cells at the time points indicated and assayedby Northern transfer analysis employing the original IκB cDNA cloneinsert as probe (Sporn et al., 1990). Times analyzed were fieshlyisolated monocytes (T_(o)), 30 minutes (30') and 1, 2, 4, and 8 hourspost-adhesion to Type IV collagen coated plates. Levels of RNA werenormalized by comparing intensity of ethidium bromide-stained 18 and 28sRNA bands.

FIG. 7B shows monocytes plated on plastic dishes either uncoated orpre-treated with Type IV collagen, fibronectin, fibronectin complexedwith anti-fibronectin (Eierman et al., 1989). RNA was extracted at 4hours and analyzed by Northern blotting using the IκB probe. RNA fromendometiosis-derived inflammatory peritoneal macrophages and freshlyisolated neutrophils (PMN) were also analyzed.

FIG. 7C shows RNA from monocytes and various cell lines were analyzed bysemi-uantitative PCR techniques to determine constitutive and induciblelevels of IκB mRNA. RNA samples included human umbilical veinendothelium (HUVE) with or without 4 hours stimulation with LPS; HeLa(carcinoma), RAJI (B-cell), HSB (T-cell) or S68 (glioblastoma) cells.Serial dilutions of 4 hours adhered monocyte cDNA was used forquantitative purposes. For comparison, cDNA from fresh monocytes and 4hours adhered monocytes were examined for expression of the NFκBtranscript.

DETAILED DESCRIPTION OF THE INVENTION

The invention described herein draws on previously published work andpending patent applications. By way of example, such work consists ofscientific papers, patents or pending patent applications. All of thesepublications and applications, cited previously or below are herebyincorporated by reference.

The present invention concerns the isolation, identification, cloning,and expression of a particular factor, hereinafter referred to as NF-κBtranscriptional activator inhibitor factor, or IκB. The inhibitor hasbeen characterieed with respect to certain of its molecular and chemicalproperties. Each of these will be discussed separately below.

Before discussing the subject invention IκB inhibitor, it is importantto be aware that the inhibitor described herein consists ofproteinaceous material having a defined chemical structure. However, theprecise structure of the inhibitor depends on a number of factors,particularly chemical modifications known to occur to proteins. Forexample, since all proteins contain ionizable amino and carboxyl groupsit is, of course, apparent that the inhibitor may be obtained in acidicor basic salt form, or in neutral form. It is further apparent, that theprimary amino acid sequence may be augmented by derivatiztion usingsugar molecules (glycosylation) or by other chemical derivatizationsinvolving covalent, or ionic attachment to the inhibitor with, forexample, lipids, phosphate, acetyl groups and the like, often occurringthrough association with saccharides. These modifications may occur invitro, or in vivo, the latter being performed by a host cell throughpost-translational processing systems. It will be understood that suchmodifications, regardless of how they occur, are intended to come withinthe definition of the IκB inhibitor so long as the activity of theprotein, as defined below, is not destroyed. It is to be expected, ofcourse, that such modifications may quantitatively or qualitativelyincease or decrease the biological activity of the molecule, and suchchemically modified molecules are also intended to come within the scopeof the invention.

"Cells" or "recombinant host" or "host cells" are often usedinterchangeably as will be clear from the context. These terms includethe immediate subject cell, and, of course, the progeny thereof. It isunderstood that not all progeny are exactly identical to the parentalcell, due to chance mutations or differences in environment.

As used herein the term "transformed" in describing host cell culturesdenotes a cell that has been genetically engineered to produce aheterologous protein that possesses the activity of the native protein.Examples of transformed cells are described in the examples of thisapplication. Bacteria are preferred microorganisms for producing theprotein. Synthetic protein may also be made by suitable transformedyeast and mammalian host cells.

"Operably linked" refers to juxtaposition such that the normal functionof the components can be performed Thus, a coding sequence "operablylinked" to control sequences refers to a configuration wherein thecoding sequence can be expressed under the control of these sequences.

"Control sequences" refers to DNA sequences necessary for the expressionof an operably linked coding sequence in a particular host organism. Thecontrol sequences which are suitable for procaryotes, for example,include a promoter, optionally an operator sequence, a ribosome bindingsite, and possibly, other as yet poorly understood, sequences.Eucaryotic cells are known to utilize promoters, polyadenylationsignals, and enhancers.

"Expression system" refers to DNA sequences containing a desired codingsequence and control sequences in operable linkage, so that hoststransformed with these sequences are capable of producing the encodedproteins. In order to effect transformation, the expression system maybe included on a vector, however, the relevant DNA may then also beintegrated into the host chromosome.

As used herein, the term "pharmaceutically acceptable" refers to acarrier medium which does not interfere with the effectiveness of thebiological activity of the active ingredients and which is not toxic tothe hosts to which it is administered. The admitration(s) may take placeby any suitable technique, including subcutaneous and parenteraladministration, preferably parenteral. Examples of parenteraladministration include intravenous, intraarterial, intramuscular, andintraperitoneal, with intravenous being preferred.

Finally, it is important to note that while the activity of theinhibitor IκB has been discussed as applied to regulating thetranscriptional activity of NF-κB on the expression of genes involved inthe inflammatory response or viral infection, it will be apprated thatits scope of inhibitory activity is wider as indicated by the presenceof NF-κB in numerous cell lines not involved in inflammation or viralinfection. Thus, as to the expression of these genes, IκB can beexpected to be useful to identify inhibitors or stimulators of theirexpression as well.

I. Identification of a cDNA Sequence that Encodes IκB

A. General Cloning Techniques:

Establishing a cDNA library containing the cDNA sequence that encodes atruncated cytokine inhibitor, identification of the cDNA sequence, andsubcloning and expressing the sequence makes use of numerous methodsknown to the skilled practitioner. A general description of the methodsand materials used is presented here for the convenience of the reader.More specifically, construction of suitable vectors containing thedesired cytokine coding sequence employs standard ligation andrestriction methods wherein isolated vectors, DNA sequences, orsynthesized oligonucleotides are cleaved, tailored, and religated in theform desired.

Site specific DNA cleavage is performed by treating with suitablerestriction enzyme(s) under conditions which are generally understood inthe art, and the particulars of which are specified by the manufacturerof these commercially available restriction enzymes. See, e.g., NewEngland Biolabs, Product Catalog. In general, about 1 μg of plasmid orDNA sequence is cleaved by one unit of enzyme in about 20 μl of buffersolution. In the examples herein, typically, an excess of restrictionenzyme is used to insure complete digestion of the DNA substrate.Incubation times of about one hour to two hours at about 37° C. areworkable, although variations can be tolerated. After each incubation,protein is removed by extraction with phenol/chloroform, and may befollowed by ether extraction, and the nucleic acid recovered formaqueous fractions by precipitation with ethanol followed bychromatography using a Sephadex G-50 spin column. If desired, sizeseparation of the cleaved fragments may be performed by polyacrylamidegel or agarose gel electrophoresis using standard techniques. A generaldescription of size separations is found in Methods in Enzymology, 1980,65:499-560.

Restriction cleaved fragments may be blunt ended by treating with thelarge fragment of E. coli DNA polymerase I, that is, the Klenowfragment, in the presence of the four deoxynucleotide triphosphates(dNTPs) using incubation times of about 15 to 25 minutes at 20 to 25° C.in 50 mM Tris pH 7.6, 50 mM NaCl, 6 mM MgCl₂, 6 mM DTT and 10 mM dNTPs.After treatment with Klenow, the mixture is extracted withphenol/chloroform and ethanol precipitated. Treatment under appropriateconditions with S1 nuclease results in hydrolysis of single-strandedportions.

Ligations are performed in 15-30 μl volumes under the following standardconditions and temperatures: 20 mM Tris-Cl pH 7.5, 10 mM MgCl₂, 10 mMDTT, 33 μg/ml BSA, 10 mM-50 mM NaCl, and 1 mM ATP, 0.3-0.6 (Weiss) unitsT4 DNA ligase at 14° C. for "sticky end" ligation, or for "blunt end"ligations 1 mM ATP was used, and 0.3-0.6 (Weiss) units T4 ligase.Intermolecular "sticky end" legations are usually performed at 33-100μg/ml total DNA concentration. In blunt end ligations, the total DNAconcentration of the ends is about 1 μM.

In vector construction employing "vector fragments," the vector fragmentis commonly treated with bacterial alkaline phosphatase (BAP) in orderto remove the 5' phosphate and prevent religation of the vector. BAPdigestions are conducted at pH 8 in approximately 150 mM Tris, in thepresence of Na⁺ and Mg⁺² using about 1 unit of BAP per μg of vector at60° C. for about 1 hour. Nucleic acid fragments are recovered byextracting the preparation with phenol/chloroform, followed by ethanolprecipitation. Alternatively, religation can be prevented in vectorswhich have been double digested by additional restriction enzymedigestion of the unwanted fragments.

In the constructions set forth below, correct ligations are confirmed byfirst transforming the appropriate E. coli strain with the ligationmixture. Successful transformants are selected by resistance toampicillin, tetracycline or other antibiotics, or using other markersdepending on the mode of plasmid construction, as is understood in theart. Miniprep DNA can be prepared from the transformants by the methodof D. Ish-Howowicz et al., 1981, Nucleic Acids Res., 9:2989 and analyzedby restriction and/or sequenced by the dideoxy method of F. Sanger eta., 1977, PNAS (USA)74:5463 as further described by Messing et al.,1981, Nucleic Acids Res., 9:309, or by the method of Maxam et al., 1980,Methods in Enzymology, 65:499.

Host strains used in cloning in M13 consists of E. coli strainssusceptible to phage infection, such as E. coli K12 strain DG98 areemployed. The DG98 strain has been deposited with ATCC Jul. 13, 1984 andhas Accession No. 1965.

Depending on the host cell used, transformation is done using standardtechniques appropriate to such cells. The calcium treatment employingcalcium chloride, as described by Cohen, S. N. el al., 1972, PNAS (USA)69:21 10, and modifications as described by Hanahan, D., 1983, J. Mol.Biol., 116:557-580 are used for procaryotes or other cells which containsubstantial cell wall barriers. Infection with Agrobacterium tumefaciens(Shaw et al., 1983, Gene 23:315) is used for certain plant cells.Transformations into yeast are carried out according to the method ofVan Solingen et al., 1977, J. Bacterial 130:946 and Hsiao et al., 1979,PNAS (USA) 76:3829.

Several transfection techniques are available for mammalian cellswithout such cell walls. The calcium phosphate precipitation method ofGraham and van der Eb, 1978, Virology, 52:546 is one method.Transfection can be carried out using a modification (Wang et al., 1985,Science 228:149) of the calcium phosphate co-precipitation technique.Another transfection technique involves the use of DEAE-dextran(Sompayrac, L. M. et al., 1981, PNAS (USA), 78:7575-7578).Alternatively, Lipofection refers to a transfection method which uses alipid matrix to transport plasmid DNA into the host cell. The lipidmatrix referred to as Lipofectin Reagent is available from BRL.

Synthetic oligonucleotides are prepared by the triester method ofMatteucci et al., 1981, J. Am Chem. Soc. 103:3185 or using commerciallyavailable automated oligonucleotide synthesizers. Kinasing of singlestrands prior to annealing or for labeling is achieved using an excess,e.g., approximately 10 units of polynucleotide kinase to 0.1 mmolesubstrate in the presence of 50 mM Tris, pH 7.6, 10 mM MgCl₂, 5 mMdithiothreitol, 1-2 mM ATP, 1.7 pmoles ³² P-ATP (2.9 mCi/mmole), 0.1 mMspermidine, 0.1 mM EDTA.

A specific nucleic acid sequence may be cloned into a vector by usingprimers to amplify the sequence which contain restriction sites on theirnon-complementary ends according to the general methods as disclosed inU.S. Pat. No. 4,683,195, issued Jul. 28, 1987, U.S. Pat. No. 4,683,202,issued Jul. 28, 1987, and U.S. Pat. No. 4,800,159, issued Jan. 24, 1989the latter of which is incorporated herein by reference in its entirety.A modification of this procedure involving the use of the heat stableThermus aquaticus (Taq) DNA polymerase has been described andcharacterized in European Patent Publication No. 258,017, published Mar.2, 1988 incorporated herein by reference in its entirety. Also useful isthe Thermal Cycler instrument (Percin-Elmer-Cetus) which has beendescribed in European Patent Publication No. 236,069, published Sep. 9,1987 also incorporated herein by reference in its entirety.

Generally, the nucleic acid sequence to be cloned is treated with oneoligonucleotide primer for each strand and an extension product of eachprimer is synthesized which is complementary to each nucleic acidstrand. An alternative to the use of plasmid DNAs encoding thelymphokines of interest as template for polymerase chain reaction(hereinafter referred to as PCR) is the use of RNA from any cellproducing these lymphokines as template for PCR as described in U.S.Pat. No. 4,800,159. If RNA is the available starting material, theextension product synthesized from one primer when separated from itscomplement can serve as template for synthesized of the extensionproduct of the other primer. As previously mentioned, each primercontains a restriction site on its 5' end which is the same as ordifferent from the restriction site on the other primer. Aftersufficient amplification has occurred the amplification products aretreated with the appropriate restriction enzyme(s) to obtain cleavedproducts in a restriction digest The desired fragment to be cloned isthen isolated and ligated into the appropriate cloning vector.

For portions of vectors derived from IκB cDNA or genomic DNA whichrequire sequence modifications, site-specific primer directedmutagenesis is used. This technique is now standard in the art, and isconducted using a primer synthetic oligonucleotide complementary to asingle stranded phage DNA to be mutagenized except for limitedmismatching, representing the desired mutation. Briefly, the syntheticoligonucleotide is used as a primer to direct synthesis of a strandcomplementary to the phage, and the resulting double-stranded DNA istransformed into a phage-supporting host bacterium. Cultures of thetransformed bacteria are plated in top agar, permitting plaque formationfrom single cells which harbor the phage.

Theoretically, 50% of the new plaques will contain the phage having, asa single strand, the mutated form; 50% will have the original sequence.The plaques are transferred to nitrocellulose filters and the "lifts"hybridized with kinased synthetic primer at a temperature which permitshybridization of an exact match, but at which the mismatches with theoriginal strand are sufficient to prevent hybridization. Plaques whichhybridize with the probe are then picked and cultured, and the DNA isrecovered. Details of site specific mutation procedures are describedbelow in specific examples.

In the constructions set forth below, correct ligations for plasmidconstruction are confirmed by first transforming E. Coli strain MM294,or other suitable host, with the ligation mixture. Successfultrasformants are selected by ampicillin, tetracycline or otherantibiotic resistance or using other markers, depending on the mode ofplasmid construction, as is understood in the art. Further screening oftransformants is possible using the technique of colony hybridizationessentially as described in Maniatis, T. et al. (supr:312-328). Briefly,colonies are lifted onto nitrocellulose filters and sequentially placedon each of four Whatman filters each saturated with one of the followingsolutions: (1) in 10% SDS; (2) 0.5 M NaOH/1 M NaCl; (3) 1.5 M NaCl, 1.5M Tris pH 8.0; (4) 2×SSC for approximately 5 minutes each. After celllysis and binding the DNA, filters were prehybridized for 0.5 to 1 hourat 42° C. in hybridization buffer containing 30% formamide followed byhybridizaton for 1-2 hrs at 42° C. Filters were washed three times in2×SSC and 0.1% SDS until background was reduced.

Plasmids from the transformants are then prepared according to themethod of Clewell et al., 1969, PNAS (USA) 62:1159, optionally followingchloramphenicol amplification (Clewell, 1972, J. Bacterial 110:667). Theisolated DNA is analyzed by restriction and/or sequenced by the dideoxymethod of Sanger et al., 1977, PNAS (USA), 74:5463 as further describedby Messing et al., 1981, Nucleic Acids Res. 9:309, or by the method ofMaxam et al., 1980, Methods in Enzymology 65:499.

The expression of DNA that encodes IκB inhibitor can be carried out in awide variety of cell types. Procaryotes most frequently are representedby various strains of E. coli. However, other microbial strains may alsobe used, such as bacilli, for example, Bacillus subtilis, variousspecies of Pseudomonas, or other bacterial strains. In such procaryoticsystems, plasmid vectors which contain replication sites and controlsequences derived from a species compatible with the host are used. Forexample, E. coli is typically transformed using derivatives of pBR322, aplasmid derived from an E. coli species by Bolivar et al., 1977, Gene2:95. pBR322 contains genes for ampicillin and tetracycline resistance,and thus provides additional markers which can be either retained ordestroyed in constructing the desired vector. Commonly used procaryoticcontrol sequences, which are defined herein to include promoters fortranscription initiation, optionally with an operator, along withribosome binding site sequences, include such commonly used promoters asthe beta-lactamase (penicillinase) and lactose (lac) promoter systems(Chang et al., 1977, Nature 198:1056), the tryptophan (trp) promotersystem (Goeddel et al., 1980, Nucleic Acids Res. 8:4057) and the lambdaderived P_(L) promoter (Shimatake et al., 1981, Nature 292:128), andN-gene ribosome binding site, which has been made useful as a portablecontrol cassette, U.S. Pat. No. 4,711,845, issued Dec. 8, 1987 andincorporated herein by reference in its entirety, which comprises afirst DNA sequence that is the P_(L) promoter operably linked to asecond DNA sequence corresponding to the N_(RBS) upstream of a third DNAsequence having at least one restriction site that permits cleavagewithin 6 bp 3' of the N_(RBS) sequence. U.S. Pat. No. 4,666,848 issuedMay 19, 1987 and incorporated herein by reference in its entiretydiscloses additional vectors with enhanced expression capabilities. Alsouseful is the phosphatase A (phoA) system described by Chang et al., inEuropean Patent Publication No. 196,864, published Oct. 8, 1986,incorporated herein by reference. However, any available promoter systemcompatible with procaryotes can be used.

In addition to bacteria, eucaryotic microbes, such as yeast, may also beused as hosts. Laboratory strains of Saccharomyces cerevisiae, Baker'syeast, are most used, although a number of other strains are commonlyavailable. While vectors employing the 2 micron origin of replicationare illustrated (Broach, 1983, Meth, Enz, 101:307; U.S. Pat. No.4,803,164 incorporated herein by reference in its entirety), otherplasmid vectors suitable for yeast expression are known (see, forexample, Stinchcomb et al., 1979, Nature 282:39, Tschempe et al., 1980,Gene 10:157 and Clarke et al., 1983, Meth. Enz. 101:300). Controlsequences for yeast vectors include promoters for the synthesis ofglycolytic enzymes (Hess et al., 1968, J. Adv. Enzyme. Req. 7:149;Holland et al., 1978, Biochemistry 17:4900).

Additional promoters useful in yeast host microorganisms and known inthe art include the promoter for 3-phosphoglycerate kinase (Hitzeman etal., 1980, J. Biol. Chem. 255: 2073), and those for other glycolyticenzymes, such as glyceraldehyde-3-phosphate dehydrogenase, hexokinase,pyruvate decarboxylase, phosphofructokinase, glucose-6phosphateisomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphateisomerase, phosphoglucose isomerase, and glucokinase. Other promoters,which have the additional advantage of transcription controlled bygrowth conditions, are the promoter regions for alcohol dehydrogenase 2,isocytochrome C, acid phosphatase, degrdative enzymes associated withnitrogen metabolism, and enzymes responsible for maltose and galactoseutilization (Holland, supra).

It is also believed that terminator sequences are desirable at the 3'end of the coding sequences. Such terminators are found in the 3'untranslated region following the coding sequences in yeast-derivedgenes. Many of the vectors illustrated contain control sequences derivedfrom the enolase gene containing plasmid peno46 (Holland et al., 1981,J. Biol. Chem. 256:1385) or the LEU2 gene obtained form YEp13 (Broach etal., 1978, Gene 8:121); however, any vector containing a yeastcompatible promoter, origin of replication and other control sequencesis suitable.

It would be possible to express IκB in eucaryotic host cell culturesderived from multicellular organisms. See, for example, Tissue CultureAcademic Press, Cruz and Patterson, editors (1973). Useful host celllines include murine myelomas N51, VERO and HeLa cells, and Chinesehamster ovary (CHO) cells. Expression vectors for such cells ordinarilyinclude promoters and control sequences compatible with mammalian cellssuch as, for example, the commonly used early and late promoters fromSimian Virus 40 (SV 40) (Fiers et al., 1978, Nature, 273:113) viralpromoters such as those derived from polyoma, Adenovirus 2, bovinepapilloma virus, or avian sarcoma viruses, or immunoglobulin promotersand heat shock promoters. A system for expressing DNA in mammaliansystems using the BPV as a vector is disclosed in U.S. Pat. No.4,419,446, incorporated herein by reference in its entirety. Amodification of this system is described in U.S. Pat. No. 4,601,978,incorporated herein by reference in its entirety. General aspects ofmammalian cell host system transformations have been described by Axelin U.S. Pat. No. 4,399,216 issued Aug. 16, 1983. Also useful is geneamplification in eucaryotic cells as described by Ringold in U.S. Pat.No. 4,656,134, issued Apr. 7, 1987, incorporated herein by reference inits entirety. It now appears also that "enhancer" regions are importantin optimng expression; these are, generally, sequences found upstream ofthe promoter region. Origins of replication may be obtained, if needed,from viral sources. However, integration into the chromosome is a commonmechanism for DNA replication in eukaryotes.

Plant cells are also now available as hosts, and control sequencecompatible with plant cells such as the nopaline synthase promoter andpolyadenylation signal sequences (Depicker et al., 1982, J. Mol. Appl.Gen., 1:561) are available. Additionally, methods and vectors fortransformation of plant cells have been disclosed in PCT Publication No.WO 85/04899, published Nov. 7, 1985, and incorporated herein byreference in its entirety.

Host strains typically used in cloning, expression and sequencing ofrecombinant constructs are as follows. For cloning, sequencing, and forexpression of construction under control of most bacterial promoters, E.coli strain MM294 obtained from E. coli Genetic Stock Center GCSC #6135,may be used as the host. For expression under control of the P_(L)N_(RBS) promoter, E. coli strain K12 MC1000 λ lysogen, N₇ N₅₃ cI857SusP₈₀, a strain deposited with the American Type Culture Collection(ATCC 39531), may be used. E. coli DG116, which was deposited with theATCC (ATCC 53606) on Apr. 7, 1987, may also be used.

For M13 phage recombinant, E. coli strains susceptible to phageinfection, such as E. coli K12 strain DG98, are employed. The DG98strain has been deposited with the ATCC (ATCC No. 39768) on Jul. 13,1984.

Mamunalian expression has been accomplished in COS-A2 cells and also canbe accomplished in COS-7, and CV-1, hamster and murine cells. Insectcell-based expression can be in Spodoptera frugiperda.

B. Establishment of a cDNA Library:

A full length cDNA sequence that encodes the IκB inhibitor may beobtained using molecular biology techniques well known in the art, withthe noted exceptions detailed below.

Several procedures are available for identifying the relevant cDNAsequences. The preferred procedures is to generate a library using RNAisolated from adherent monocytes, but a library can be generated fromvirtually any source of biological material that expresses theinhibitor, indeed, cDNA libraries can even be purchased commercially.Monocytes are the preferred starting material because adherence to anappropriate surface induces the expression of the IκB inhibitor.

An illustrative procedure for making a cDNA library containing theinhibitor sequences consists of isolating total cytoplasmic RNA from asuitable starting material, and further isolating messenger RNAtherefrom. The latter can be further fractionated into Poly (A+)messenger RNA, which in turn may be fractionated further still into Poly(A+) messenger RNA fractions containing cytokine inhibitor messengerRNA. The messenger RNA can then be reverse transcribed and cloned into asuitable vector to form the cDNA library.

More specifically, the starting material (i.e., tissue, cells) is washedwith phosphate buffered saline, and a non-ionic detergent, such asethylene oxide, polymer type (NP40) is added in an amount to lyse thecellular, but not nuclear membranes, generally about 0.3%. Nuclei canthen be removed by centrifugation at 1,000×g for 10 minutes. Thepost-nuclear supernatant is added to an equal volume of TE (10 mM Tris,1 mM ethylenediaminetetraacetic acid (EDTA), pH 7.5) saturatedpheno/chloroform (1:1) containing 0.5% sodium dodecyl sulfate (SDS) and10 mM EDTA. The supernatant is re-extracted 4 times and phase separatedby centrifugation at 2,000×g for 120 minutes. The RNA is precipitated byadjusting the samples to 0.25 M NaCl, adding 2 volumes of 100% ethanoland storing at -20° C. The RNA is then pelleted at 5,000×g for 30minutes, washed with 70% and 100% ethanol, and dried. This representsthe total cytoplasmic RNA.

Alternatively, total cytoplasmic RNA may be isolated using the guanidineisothiocyanate-cesium chloride method as described by Chirgwin et al.,1979, Biochemistry, 18:5294.

Polyadenylated (Poly A+) messenger RNA (mRNA) can be obtained from thetotal cytoplasmic RNA by chromatography on oligo (dT) cellulose (J. Avivet al., 1972, PNAS, 69:1408-1412). The RNA is dissolved in ETS (10 mMTris, 1 mM EDTA, 0.5% SDS, pH 7.5) at a concentration of 2 mg/ml. Thissolution is heated to 65° C. for 5 minutes, then quickly chilled to 4°C. After bringing the RNA solution to room temperature, it is adjustedto 0.4 M NaCl and slowly passed through an oligo (dT) cellulose columnpreviously equilibrated with binding buffer (500 mM NaCl, 10 mM Tris, 1mM EDTA, pH 7.5) The flow-through is passed over the column twice more,and the column washed with 10 volumes of binding buffer. Poly (A+) mRNAis eluted with aliquots of ETS, extracted once with TE-saturated phenolchloroform and precipitated by the addition of NaCl to 0.2 M and 2volumes of 100% ethanol. The RNA is reprecipitated twice, washed once in70% and then 100% ethanol prior to drying. The poly (A+) mRNA can thenbe used to construct a cDNA library.

cDNA can be made from the enriched mRNA fraction using oligo (dT)priming of the poly A tails and AMV reverse transcriptase employing themethod of H. Okayama et al., 1983, Mol. Cell Biol. 3:280, incorporatedherein by reference.

Other methods of preparing cDNA libraries are, of course, well known inthe art. One, now classical, method uses oligo (dT) primer, reversetranscriptase, tailing of the double stranded cDNA with poly (dG) andannealing into a suitable vector, such as pBR322 or a derivativethereof, which has been cleaved at the desired restriction site andtailed with poly (dC). A detailed description of this alternate methodis found, for example, in U.S. Ser. No. 564,224, filed Dec. 20, 1983,and assigned to the same assignee, incorporated herein by reference.

A preferred method by which a cDNA clone that encodes the IκB inhibitormay be identified is to employ a cDNA library that is produced using RNAobtained from induced monocytes, and to detect individual clones thatdifferentially hybridize to cDNA probes produced using RNA from inducedand uninduced monocytes. Clones that preferentially hybridize to cDNAprobes produced from induced but not uninduced monocyte RNA will containcDNA that encodes the cytokine inhibitor of the instant invention.

cDNA inserts may be sequenced using known techniques. The preferredtechnique is to subclone the inserts into an appropriate vector, anexemplary vector being pGEM blue (Promega Biotec. Madison, Wis. Corp.),and sequence the double stranded DNA using the dideoxy chain terminationmethod described by Sanger et al., 1977, PNAS (USA), 74:5463. Sequencingis conveniently performed using commercially available kits, preferablythe Sequenase sequencing kit produced by United States Biochemical Co.Cleveland, Ohio, and using suitable primers, such as T7 and SP6obtainable from Promega Biotec. Madison, Wis., and sequence specificprimers.

C. IκB Assay:

To confirm that a cDNA sequence does encode IκB, gel mobility shiftassays may be performed. The assay is based on the observation thatNF-κB binds to a defined DNA in the absence but not the presence of IκB.The assay consists of detecting the effect of IκB, produced byreticulocyte translation, on the binding of NF-κB to a Class I MHCenhancer sequence, TGGGGATTCCCCA (SEQ ID NO: 2). Previously, thisenhancer sequence has been demonstrated to bind to NF-κB (Baldwin, andSharp, P., 1988 PNAS (USA), 85:723-727). The source of NF-κB in theassays may be nuclear extracts of a variety of cell types, but thepreferred source is mitogen and phorbol ester induced Jurkat T-cells.The induction NF-κB in this cell line is well documented (Nabel, G. andBaltimore, D., 1987, Nature, 326:711-713).

The gel mobility shift assay is conducted by incubating appropriateamounts of the following materials: nuclear extracts obtained fromJurkat cells and/or rabbit reticulocyte lysates, either with IκB mRNA orwithout, and an appropriate labelled MHC enhancer binding probe. Thereaction is conducted in a buffered solution containing appropriateamounts of the following: sodium chloride, EDTA, DTT, poly dI-dC(Pharmacia) and glycerol. The reaction is preferably conducted at roomtemperature for about 15 minutes and then subjected to electrophoresison a non-denaturing 5% polyacrylamide gel using a Tris/glycine/EDTAbuffer as described by Baldwin, A., 1990, DNA & Protein Eng. Tech.,2:73-76. The gel is dried and autoradiographed overnight using knowntechniques in the art.

Using the above described gel mobility shift assay, cDNA clones thatencode IκB can be identified by their ability to eliminate or reduce thebinding of NF-κB to the MHC enhancer DNA binding probe.

Further tests may be conducted to confirm that a cDNA sequence encodesIκB and not a molecule that non-specifically binds to a variety of DNAenhancer binding proteins. These tests may be conducted using the gelmobility shift assay essentially as described above, but with thesubstitution of a different DNA enhancer sequence and/or a differenttranscription regulator for NF-κB. A variety of such proteins weretested including KBF1, MLTF, Oct-1 or H2T1.

It will be appreciated by those skilled in the art, that knowledge ofthe DNA sequence that encodes IκB enables the synthesis of nucleotideprobes that can be used to measure the expression of IκB in biologicalsystems using techniques known in the art. This in turn will facilitatethe identification of chemicals that induce or suppress the expressionof IκB. The identification of such chemicals would have value asmedicaments, while a determination of the levels of IκB expression wouldhave diagnostic value.

Having described what the applicants believe their invention to be, thefollowing examples are presented to illustrate the invention, and arenot to be construed as limiting the scope of the invention.

EXAMPLE 1

Cloning of IκB

The preferred procedure for constructing a cDNA library that contains acDNA sequence that encodes the IκB inhibitor is to generate the libraryfrom RNA isolated from adherent monocytes. These procedures aredescribed by Sporn, S. A. et al., J. of Immunol, 1990, 144:4434.Briefly, the starting material consists of adherent monocytes. Monocytesmay be obtained fresh from human volunteers, or from the American RedCross. In both instances, the monocytes are isolated from whole bloodinitially in the form of a mononuclear cell fraction prepared byFicoll-Hypaque sedimentation methods known in the art. Boyun, A., 1968,Scandinavian J. of Clinical Lab. Invest., 21:77. The monocytes are thenisolated from the mononuclear fraction by density fractionation usingPercoll. Ulmer, A. J., and Flad, D. H., 1979, J. of ImmunologicalMethods, 30: 1. Alternatively, monocytes may be isolated by plating themonto plastic tissue culture dishes as described by Eierman, D. F., etal., 1989, J. of Immunology, 142:1970.

The monocytes are induced to express of the IκB inhibitor by seeding themonocytes onto tissueculture plates or collagen coated tissue cultureplates as generally described by Eierman, D. F., et al., 1989, J.Immunol., 142:1970. A variety of materials may be used to coat thetissue culture plates to effect monocyte adherence, and includefibronectin. Briefly, 100 mm tissue culture plates are coated with 100μg/ml of human fibronectin in phosphate buffered saline (PBS) for 45minutes at 37° C. Excess fibronectin is removed by washing the plateswith PBS and the plates air dried before use. Monocytes are seeded ontothe plates and are adherent to the tissue culture plates for at leastthe 30 minutes prior to the total RNA being extracted therefrom. Themonocytes are cultured in RPMI 1640 media containing 20 μg/ml ofgentamicin sulfate at 37° C. in an atmosphere of 95% air/5%CO₂.Generally, about 1-2×10⁷ cells are seeded per 100 mm dish

Next, adherent monocytes are lysed after removing the culture medium byadding 3.5 ml of a solution containing 4 M guanidinium thiocyanatesolution previously prepared by mixing 50 g of Fluka pure grade materialwith 0.5 g of sodium N-lauroylsarcosine (final concentration 0.5%), 2.5ml of 1 M sodium citrate, pH 7.0 (25 mM), and 0.7 ml of2-mercaptoethanol (0.1 M). The solution is made up to 100 ml withdeionized water, and filtered to remove any insoluble material. The pHwas adjusted to 7 with 1 M NaOH.

Next, the monocyte RNA is separated from the guanidinium thiocyanatehomogenate by ultra centrifugation through a dense cushion of cesiumchloride. Technical grade cesium chloride is made 5.7 M and bufferedwith 0.1 M EDTA, pH 7, or 25 mM sodium acetate or citrate, pH 5. Thesolution is sterilized with 0.2% diethyl pyrocarbonate, and filteredthrough a 0.45 μm Millipore filter. The monocyte RNA in the guanidiniumthiocyanate is then separated from the guanidinium thiocyanate byultracentrifugation through the cesium chloride cushion. The RNA pelletsthat form after the ultracentrifugation are redissolved if necessary bybrief heating at 68° C. in a water bath, or by first extracting excesscesium chloride from the RNA pellets with ethanol and drying withnitrogen. RNA isolated in this manner may be used to prepare anappropriate cDNA library.

Total RNA isolated as described above may be used for construction of acDNA library using those methods described by Watson and Jackson, 1985,DNA Cloning, 1:79, "A Practical Approach", (D. M. Glover, ed.), IRLPress, Oxford; and Huynh, et al., 1985, "Constructing and ScreeningLibraries in Lambda GT10 and Lambda GT11", DNA Cloning, 1:49, APractical Approach, (D. M. Glover, ed.), IRL Press, Oxford. This methodentails converting the RNA to double stranded cDNA using AMV reversetranscriptase and the Klenow fragment DNA polymerase 1, as is known inthe art EcoRI linkers were ligated to the double stranded cDNAfragments, size selected and packaged into λ gt 10 vector using acommercially available packaging extract, Gigapack (Stratagene, SanDiego, Calif.). This library contained about 5.3×10⁶ recombinants at afrequency of about 7×10⁷ per μg of DNA.

From the library described above, a sub-library was derived by selecting4,000 clones that do not hybridize to a ³² P-labelled first-strand cDNAprobe that was made using RNA obtained from uninduced monocytes.

The sub-library described above was screened by differentialhybridization with ³² P-labelled first-stand cDNA probes prepared byreverse transcription of RNA isolated from monocytes that adhere foreither 30 minutes or 4 hours, or from controlled non-adherent monocytes.Those plaques which exhibited hybridization with the cDNA probe madefiAm adhered monocytes compared to non-adhered monocytes were selected,and rescreened with the probe. This resulted in the isolation of a 350base pair fragment termed MAD-3, which represents a partial sequence ofIκB. Note that the MAD-3 sequence is nearly identical to bases 783-1117of the IκB cDNA with the exception that there is an additional triplet,TGA, in MAD-3. The sequence of MAD-3 is shown in FIG. 1. A full lengthIκB clone was obtained using MAD 3 to probe a second cDNA library madefrom mRNA isolated from adhered monocytes and neutrophils. The mRNA wasreversed transcribed and the cDNA cloned into the pcDNA 1 vector. Thisvector is available from In Vitrogen Corporation. Screening of thislibrary yielded several full-length clones, and one of these wassequenced.

EXAMPLE 2

DNA Sequence of IκB

cDNA inserts were subcloned into the double-stranded vector pGEM blue(Promega Biotec, Madison, Wis.). dscDNA sequencing was performed by thedideoxy chain termination method (as described in Sanger, F. S., et al.,1977, PNAS (USA), 74:5463) by using the Sequenase sequencing kit (UnitedStates Biochemical Co., Cleveland, Ohio) with T7 and SP6 primers(Promega), as well as sequence-specific oligonucleotide primers. FIG. 2shows the cDNA sequence of IκB.

The sequence of IκB shows that it is about 1550 base pairs in length,and extends 94 base pairs 5' of a Kozak consensus sequence for thepredicted start site of translation. The 3' untranslated region displaysthree ATTTA (SEQ ID NO: 1) motifs that are associated with rapidturnover of mRNA (Kaput D., et al., 1986, PNAS (USA), 83:1670-1674). Thepoly A tail begins at the end of the base pair 1550.

The deduced amino acid sequence of IκB is shown in FIG. 2, and is basedon the cDNA sequence. The protein would have 317 amino acids, and thushave approximate molecular weight of 34 kD. The molecule ischaracterized in having three apparent domains. The first, theN-terminal domain, exhibits a 72 amino acid hydrophilic stretch thatcontains a consensus sequence, DEEYEQMVK (SEQ ID NO: 3), for tyrosinephosphorylation. The second domain, the C-terminal domain, contains aconsensus sequence for PKC phosphorylation, RPSTR (SEQ ID NO: 4), and aregion rich in PEST (SEQ ID NO: 5) residues, amino acids 264-314 whichare associated with rapid protein turnover. The third domain consists ofamino acids 74-242, which comprises five tandem repeats of the ankyrinconsensus sequence (Lux S. E., et al., 1990, Nature, 344:3642). FIG. 3shows a Kyte-Doolittle hydrophilicty/hydrophobicity plot. The fiveankyrin repeats are overlined and each repeat is marked. The predictedtyrosine phosphorylation domain and the putative PKC linase targetsequences are also overlined.

EXAMPLE 3

IκB Assays

The IκB DNA sequence in the expression plasmid, pcDNA 1, was used togenerate RNA using SP6 RNA polymerase. The RNA was translated in arabbit reticulocyte lysate mixture in the presence of ³⁵ S-methionine,and the products analyzed on a 10% SDS polyacrylamide gel. As a control,mock translated lysates were run. FIG. 4A shows the results. Since thereticulocyte lysate used for translation contained an endogenousNF-κB-like activity (data not shown), the lysates were depleted for thisactivity using a DNA affinity matrix specific for NF-κB. TheseNF-κB-depleted reticulocyte lysates demonstrated virtually no Class IMHC enhancer binding activity (see FIG. 4B, lane 5). The reticulocytelysates were then used to translate either full length IκB mRNA, or mRNAderived from an AccI digest of the cDNA or were mock translated. AccIcuts the IκB cDNA at the position corresponding to amino acid 167 in thethird ankyrin repeat. The in vitr translated products, labelled with ³⁵S-methionine, were electrophoresed on a 10% SDS polyacrylamide gel. Aspredicted from the cDNA, the full length IκB mRNA and the mRNA from theAccI-digested plasmid revealed approximately 36 and 22 kD proteins (FIG.4A, lanes 1 and 2).

Briefly, the reticulocyte translation reaction was conducted as follows.2 μg of pcDNA1 containing full length IκB cDNA was digested with BamHIor with AccI. The restriction enzyme cuts downstream of the cDNA insertThe reaction digest was phenol/chloroform extracted, ethanolprecipitated and used to synthesize RNA in a 100 μl reaction for 1 hourat 37° C. using SP6 RNA polymerase following the conditions recommendedby the manufacturer (Boehringer Mannheim). The resulting RNA wasextracted twice with phenol/chloroform, ethanol precipitated andredissolved in 20 μl of water. Synthesis of RNA was confirmed byelectrophoresis using agarose gels.

However, before conducting the translation reaction, rabbit reticulocytelysates were first depleted of an endogenous NF-κB-like DNA-bindingactivity. This was performed by adding 10 μl of lysate to 20 μl of DNAaffinity resin previously washed with deionized water. This procedure isdescribed below. The binding reaction was performed, with frequentmixing, for 10 minutes at room temperature. The mixture was pelleted bybrief centrifugation in a microfuge and the supernatant was removed forin vitro translation reactions. Next, 4 μl of RNA was used for in vitrotranslation in a rabbit reticulocyte lysate system obtained from PromegaBiotech. The conditions for performing the reaction were thoserecommended by the manufacturer. The resulting ³⁵ S-methionine labelledproducts were analyzed on a 10% SDS polyacrylamide gel as described byLaemmli U., 1970, Nature, 227:680-685. The gel was dried and exposed forautoradiography using standard methods.

The DNA affinity resin contained the MHC Class I enhancer sequenceTGGGGATTCCCCA (SEQ ID NO: 2), covalently linked to cyanogen bromideactivated Sepharose 4B (Sigma). The resin was made and the purificationof NF-κB carried out essentially by the method of Kadonaga and Tjian(1986). Nuclear extracts of PMA and PHA stimulated Jurkat T-cells wereused for the NF-κB purification. Jurkat nuclear extracts were incubatedwith the resin for 20 minutes and the NF-κB was eluted with a saltgradient Only one round of DNA affinity chromatography was performed.

To determine that the IκB cDNA sequence does encode a molecule thatbinds to NF-κB, gel mobility shift assays were performed. The assayconsisted of detecting the binding of IκB produced by reticulocytetranslation to NF-κB on acrylamide gels as revealed by binding of aClass I MHC enhancer sequence, TGGGGATTCCCCA (SEQ ID NO: 2). Previously,this enhancer sequence has been demonstrated to bind to NF-κB (Baldwin,and Sharp, P., 1988 PNAS (USA), 85:723-727). The source of NF-κB in theassays was nuclear extracts of mitogen and phorbol ester induced JurkatT-cells (described below). The induction of NF-κB in this cell line iswell documented (Nabel, G. and Baltimore, D., 1987, Nature,326:711-713), and, furthermore, there is an activity having theproperties ascribable to KBF1.

The gel mobility shift assay was conducted as follows. 10 μg of nuclearextracts obtained from Jurkat cells and/or 1 μl of rabbit reticulocytelysates, either with IκB mRNA or without, and 10,000 counts/minute ofN-labelled MHC enhancer binding probe were incubated in 10 mM Tris, pH7.7,50 mM sodium chloride, 0.5 mM EDTA, 1 mM DTT, 2 μg poly dI-dC(Pharmacia) and 10% glycerol in a final volume of 20 μl. The reactionwas conducted at room temperature for 15 minutes and then subjected toelectrophoresis on a non-denaturing 5% polyacrylamide gel using aTris/glycine/EDTA buffer as described by Baldwin, A., 1990, DNA &Protein Eng. Tech. 2:73-76. Electrophoresis was conducted forapproximately 2 hours at 20 mA. The gel was dried and autoradiographedovernight at -70° C. using known techniques in the art.

The DNA/protein complexes indicated by the arrows in FIG. 4 appear byvarious criteria to be NF-κB and KBF1. Addition of the IκB programmedlysates inhibited the DNA-binding activity associated with the slowerNF-κB/DNA complex (indicated by the large arrow, FIG. 4B, lane 2) in thestimulated Jurkat T nuclear extracts and only weakly affected the factorassociated with the faster moving KBF1/DNA complex (indicated by thesmall arrow, FIG. 4B, lane 2). Addition of either lysates programmedwith the deleted mRNA or mock translated lysates did not affect eitherDNA-binding activity (FIG. 4B, lanes 3 and 4).

To further characterize the DNA-binding activities in the nuclearextracts of the PMA and PHA stimulated Jurkat cells, several assays wereperformed We first demonstrated that the two activities identified bythe arrows are specific for the MHC enhancer probe as they do notinteract with a double point mutated probe (FIG. 4C, lane 1). We havepreviously shown that this mutant probe TGCGGATTCCCOGA (SEQ ID NO: 6) isnot bound by NF-κB (Baldwin and Sharp, 1988, above). The factorsassociated with the slower and faster complexes interact equally wellwith immunoglobulin kappa and Class I MHC enhancer probes (FIG. 4C,lanes 2 and 3), consistent with these activities being NF-κB and KBF1.Finally, the two DNA/protein complexes are recognized by antibodiesagainst the p50 subunit of NF-κB (FIG. 4C, lane 4) but not by pre-immuneserum (FIG. 4C, lane 5). Thus, the IκB protein strongly inhibits anauthentic NF-κB activity from stimulated Jurkat T-cells and may inhibitthe Jurkat KBF1 activity very weakly.

Nuclear extracts were prepared from Jurkat T-cells using the method ofSwick et al., 1989, Nucleic Acids Res., 17:9291-9304. The cells weregrown in RPMI 1640 medium containing 10% fetal calf serum. If desired,the cells were stimulated with phytohemagglutinin (PHA) and phorbol12-myristate 13acetate (PMA). These were used at final concentrations of1 μg/ml and 50 ng/ml, respectively.

To demonstrate that the observed inhibition is specific for the NF-κBactivity, we analyzed the affect of the IκB protein on othercharacterized DNA-binding proteins (FIG. 5A). IκB did not inhibit theDNA-binding activity of the major late transcription factor (Carthew etal., 1985, Cell, 43:439-448; also known as USF), the Oct-1 factor(Singh, et al., 1986, Nature, 319:154-158), or H2TF1, a Class I MHCenhancer binding factor (Baldwin and Sharp, 1987). We next analyzedwhether NF-κB from another cell source would be inhibited by thetranslated IκB protein. NF-κB from nuclear extracts of freshly isolatedmonocytes was inhibited by the IκB protein, but the KBF1 activity foundin these cells was unaffected (FIG. 5B). Both the NF-κB and KBF1activities in these extracts are recognized by antibodies to the p50NF-κB subunit. Thus, the IκB protein is highly specific for NF-κB fromseveral cell sources and has little or no effect on KBF1 DNA bindingactivity (FIGS. 4B and 5B). These results are consistent with theobservation that IκB interacts with the 65 kD subunit of NF-κB, which isabsent in KBF1 (Kieran et al., 1990, Cell, 62:1007-1018). We, therefore,conclude that the IκB translation product specifically inhibits NF-κBDNA -binding activity and does not inhibit the DNA-binding activity ofKBF1, MLTF, Oct-1 or H2TF1.

The DNA-binding probes are labelled HindIII-EcoRi digests of pUCplasmids containing oligonucleotides cloned into the polylinker withBamHI restriction ends. The sequence of the Class I MHC enhancer probeis GGCTGGGGATTCCCCATCT (SEQ ID NO: 7) and the mutant MHC probe isGGCTGCGGATTCCCGATCT (SEQ ID NO: 9) (Baldwin and Sharp, 1987), thesequence of the MLTF probe is ACCCGGTCACGTGGCCTACA (SEQ ID NO: 9), thesequence of the Oct-1 probe is ATGCAAAT (SEQ ID NO: 10), and thesequence of the immunoglobulin kappa probe is CAGAGGGACTTTCCGAGA (SEQ IDNO: 11).

Thus, based on the experiments presented above, it is concluded that thecDNA sequence that encodes IκB produces a protein that specificallyinhibits NF-κB DNA binding activity, and does not inhibit the activitiesassociated with KBF1, MLTF, Oct-1, or H2TF1.

Another characteristic of IκB is that it can be released from NF-κB withsodium deoxycholate (DOC). Once IκB is released from NF-κB, NF-κB canthen bind to DNA. Thus, to further characterize IκB, we treated areticulocyte lysate programmed with IκB mRNA with sodium deoxycholate,and NP40 and the treated mixture tested in a gel mobility shift assay asdescribed previously. Endogenous NF-κB was removed by DNA affinitychromatography, as described above, to remove endogenous NF-κB/IκBcomplexes. Similar to crude nuclear extracts of stimulated JurkatT-cells, (FIG. 4B), the IκB translation product inhibits this partiallypurified NF-κB (FIG. 6, lane 2).

More specifically, 10 μg of nuclear extracts containing NF-κB wasreacted with 1 μl of IκB programmed lysates or mock translated lysatesunder the binding conditions described above. The reactions were kept atroom temperature for 10 minutes followed by the addition of 2 μg of polydI-dC and 10,000 cpm of radiolabelled DNA probe. The reactions were thenloaded onto a 5% polyacrylamide Tris/glycine/EDTA gel and analyzed asdescribed above. For the dissociation reactions, 0.8% sodiumdeoxycholate was added to the binding reactions (minus poly dI-dC andprobe) followed by 1.2% NP40. Poly dI-dC and probe were added andincubated at room temperature for 15 minutes. These reactions wereelectrophoresed and analyzed as described above. Treatment of theNF-κB/IκB reaction with sodium deoxycholate (DOC) followed by NP40incubation released NF-κB DNA-binding activity (FIG. 6, lane 3). Thus,the release of NF-κB DNA-binding activity from the reaction is derivedfrom NF-κB/IκB complexes and not from any endogenous NF-κB/IκB in theextract. Since NF-κB DNA-binding activity can be recovered fromperformed NF-κB/IκB by DOC treatment, we conclude that IκB encodes aprotein with properties of IκB.

EXAMPLE 4

Tissue Distribution of lκB

The presence of the IκB inhibitor of the instant invention in varioustissues/cells was determined using Northern blot analysis or PCR.

Northern blot analysis consisted of isolating total RNA from the tissueto be tested using the guanidine isothiocyanate-cesium chloride methodas described by Haskill et al., above. Filters were hybridized at 43° C.and washed to a final stringency of 0.2×SSC at 56° C. using IκB as aprobe.

PCR analysis was conducted using 1 μg of total RNA isolated as describedabove, whereby the RNA was converted into first strand DNA using randomhexamers as described Kawasaki et al., 1989, Detection of GeneExpression in, PCR Technology (ed. Erlich), H. A. (Stockton, N.Y.),pages 89-97. Next, amplification was carried out with a5'-TCGTCCGCGCCATGTTCCAG (SEQ ID NO: 12) (base pair 85-103) and 3'anti-sense primer GCGGATCACTTCCATGGTCAG (SEQ ID NO: 13) (base pair359-379). So that transcript frequencies could be compared from onetissue type to another, dose response curves were determined at the samePCR cycle number, 30, as test samples. Standards included IκB cDNA atvarious dilutions, as well as RNA isolated from monocytes that hadadhered for 4 hours to a substratum that induces IκB expression. NF-κBprimers were synthesized using the published sequences of Kieran et al.,1990, Cell, 62:1007-1018. The sense primer was TAGAGCAACCTAAACAGAG (SEQID NO: 14) (base pair 316-335) and the anti-sense primer,TCATTCGTGCTTCCAGTGT (SEQ ID NO: 15) (base pair 629-648).

FIG. 7A shows that IκB is not seen in freshly Percoll-isolated monocytes(T₀), but is induced by binding to Type IV collagen.

Northern analysis revealed that IκB is highly expressed in monocytesadherent to different substrates and in blood neutrophils and is alsopresent in endometriosis associated peritoneal inflammatory macrophages.These results are shown in FIG. 7B.

PCR analysis revealed constitutive expression of IκB mRNA in a number ofsamples examined (FIG. 7C). This included HSB and RAJI cells,glioblastoma cells, G82, and HUVE cells. The amount of Iκd3 could beincreased by activation of HUVE cells by LPS, causing approximately a9-fold increase in IκB expression. Adherence of HUVE cells caused a80-fold increase in expression. Expression of NF-κB is also shown for T₀and 4 hour plastic-adherent monocytes. IκB was also observed to bepresent in several melanoma cell lines, and the level of expression isenhanced 2-3-fold by exposure to PMA, but little or no increase isobserved after exposure to IL-2 or TNF (not shown).

EXAMPLE 5

Identificaticn of Medicaments

IκB may be used in a suitable assay format to identify medicaments thatenhance or inhibit gene expression. Purified recombinant or naturallyoccurring IκB may be used in combination with NF-κB to identifychemicals that inhibit the formation of IκB/NF-κB complex formation, orthat stabilize the complex once formed. Alternatively, in vitrotranscription and translation of IκB can be employed, as discussedbelow. The materials and methods for canying out these procedures aredescribed above, and incorporated herein by reference.

Chemicals that inhibit or prevent complex formation would enhance geneexpression by increasing the amount of free NF-κB to bind to anappropriate DNA sequence, while those that stabilize the complex wouldprevent or retard gene expression by regulating the amount of free NF-κBavailable.

For example, to identify chemicals that inhibit complex formation, theIκB DNA sequence in the expression plasmid, pcDNA 1, would be used togenerate RNA using SP6 RNA polymerase. The RNA may be translated in arabbit reticulocyte lysate mixture in the presence of ³⁵ S-methionine,and an aliquot combined with NF-κB in the presence or absence ofchemicals being tested for inhibitory activity. A source of NF-κB wouldbe stimulated Jurkat T-ells, prepared as described above. The reactionproducts could then be analyzed in a gel mobility shift assay. Chemicalsthat inhibit complex formation would produce little or no shift in thegel assay compared to the control.

To identify chemicals that stabilize the IκB/NF-κB complex, chemicalscan be tested for their capacity to maintain the complex in the presenceof deoxycholate. The assays for dissociating the IκB/NF-κB complex indeoxycholate/NP40 are described in Example 3, and the instant assaywould be conducted similarly but with the addition of the chemical beingtested followed by a gel shift assay. Chemicals that stabilize thecomplex would prevent IκB dissociation from NF-κB and this would bedetected by reduced binding of NF-κB to the radiolabelled MHC Class Ienchancer probe.

Although any similar or equivalent methods and materials may be employedin the practice or testing of the present invention, the preferredmethods and materials are now described. The following examples areillustrative of this invention. They are not intended to be limitingupon the scope thereof.

The present invention has been described with reference to specificembodiments. However, this application is intended to cover thosechanges and substitutions which may be made by those skilled in the artwithout departing from the spirit and the scope of the appended claims.

Deposit of Biological Materials: The following plasmid which encodes IκBhave been deposited with the American Type Culture Collection.

    ______________________________________                                        Designation       ATCC No.  Date of Deposit                                   ______________________________________                                        pC3.A in the E. coli host DH5                                                                             5-16-91                                           ______________________________________                                    

    __________________________________________________________________________    #             SEQUENCE LISTING                                                   - -  - - (1) GENERAL INFORMATION:                                             - -    (iii) NUMBER OF SEQUENCES: 18                                          - -  - - (2) INFORMATION FOR SEQ ID NO:1:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 5 base p - #airs                                                  (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                 - -     (ii) MOLECULE TYPE: DNA (genomic)                                     - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:                               - - ATTTA                 - #                  - #                  -      #             5                                                                  - -  - - (2) INFORMATION FOR SEQ ID NO:2:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 13 base - #pairs                                                  (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                 - -     (ii) MOLECULE TYPE: DNA (genomic)                                     - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:                               - - TGGGGATTCC CCA              - #                  - #                      - #      13                                                                  - -  - - (2) INFORMATION FOR SEQ ID NO:3:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 9 amino - #acids                                                  (B) TYPE: amino acid                                                          (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                 - -     (ii) MOLECULE TYPE: protein                                           - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:                               - - Asp Glu Glu Tyr Glu Gln Met Val Lys                                      1               5                                                              - -  - - (2) INFORMATION FOR SEQ ID NO:4:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 5 amino - #acids                                                  (B) TYPE: amino acid                                                          (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                 - -     (ii) MOLECULE TYPE: protein                                           - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:                               - - Arg Pro Ser Thr Arg                                                      1               5                                                              - -  - - (2) INFORMATION FOR SEQ ID NO:5:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 4 amino - #acids                                                  (B) TYPE: amino acid                                                          (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                 - -     (ii) MOLECULE TYPE: protein                                           - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:                               - - Pro Glu Ser Thr                                                          1                                                                              - -  - - (2) INFORMATION FOR SEQ ID NO:6:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 13 base - #pairs                                                  (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                 - -     (ii) MOLECULE TYPE: DNA (genomic)                                     - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:                               - - TGCGGATTCC CGA              - #                  - #                      - #      13                                                                   - -  - - (2) INFORMATION FOR SEQ ID NO:7:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 19 base - #pairs                                                  (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                 - -     (ii) MOLECULE TYPE: DNA (genomic)                                     - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:                               - - GGCTGGGGAT TCCCCATCT             - #                  - #                      - # 19                                                                   - -  - - (2) INFORMATION FOR SEQ ID NO:8:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 18 base - #pairs                                                  (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                 - -     (ii) MOLECULE TYPE: DNA (genomic)                                     - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:                               - - GCTGCGGATT CCCGATCT             - #                  - #                      - #  18                                                                   - -  - - (2) INFORMATION FOR SEQ ID NO:9:                                     - -      (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 20 base - #pairs                                                  (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                 - -     (ii) MOLECULE TYPE: DNA (genomic)                                     - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:                               - - ACCCGGTCAC GTGGCCTACA            - #                  - #                      - # 20                                                                   - -  - - (2) INFORMATION FOR SEQ ID NO:10:                                    - -      (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 8 base p - #airs                                                  (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                 - -     (ii) MOLECULE TYPE: DNA (genomic)                                     - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:                              - - ATGCAAAT                - #                  - #                  -     #           8                                                                   - -  - - (2) INFORMATION FOR SEQ ID NO:11:                                    - -      (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 18 base - #pairs                                                  (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                 - -     (ii) MOLECULE TYPE: DNA (genomic)                                     - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:                              - - CAGAGGGACT TTCCGAGA             - #                  - #                      - #  18                                                                   - -  - - (2) INFORMATION FOR SEQ ID NO:12:                                    - -      (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 20 base - #pairs                                                  (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                 - -     (ii) MOLECULE TYPE: DNA (genomic)                                     - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:                              - - TCGTCCGCGC CATGTTCCAG            - #                  - #                      - # 20                                                                   - -  - - (2) INFORMATION FOR SEQ ID NO:13:                                    - -      (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 21 base - #pairs                                                  (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                 - -     (ii) MOLECULE TYPE: DNA (genomic)                                     - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:                              - - GACTGGTACC TTCACTAGGC G           - #                  - #                      - #21                                                                   - -  - - (2) INFORMATION FOR SEQ ID NO:14:                                    - -      (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 19 base - #pairs                                                  (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                 - -     (ii) MOLECULE TYPE: DNA (genomic)                                     - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:                              - - TAGAGCAACC TAAACAGAG             - #                  - #                      - # 19                                                                   - -  - - (2) INFORMATION FOR SEQ ID NO:15:                                    - -      (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 18 base - #pairs                                                  (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                 - -     (ii) MOLECULE TYPE: DNA (genomic)                                     - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:                              - - CATTCGTGCT TCCAGTGT             - #                  - #                      - #  18                                                                   - -  - - (2) INFORMATION FOR SEQ ID NO:16:                                    - -      (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 350 base - #pairs                                                 (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                 - -     (ii) MOLECULE TYPE: DNA (genomic)                                     - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:                              - - CTGACCTGGT GTCACTCCTG TTGAAGTGTG GGGCTGATGT CAACAGAGTT AC -             #CTACCAGG     60                                                                 - - GCTATTCTCC CTACCAGCTC ACCTGGGGCC GCCCAAGCAC CCGGATACAG CA -            #GCAGCTGG    120                                                                 - - GCCAGCTGAC ACTAGAAAAC CTTCAGATGC TGCCAGAGAG TGAGGATGAG GA -            #GAGCTATG    180                                                                 - - ACACAGAGTC AGAGTTCACG GAGTTCACAG AGGACGAGCT GCCCTATGAT GA -            #TGACTGTG    240                                                                 - - TGTTTGGAGG CCAGCGTCTG ACGTTATGAG CAAAGGGGCT GAAAGAACAT GG -            #ACTTGCAT    300                                                                 - - ATTTGTACAA AAAAAAAAGT TTTATTTTTC TAAAAAAAAA AAAAAAAAAA  - #                 350                                                                        - -  - - (2) INFORMATION FOR SEQ ID NO:17:                                    - -      (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 1550 base - #pairs                                                (B) TYPE: nucleic acid                                                        (C) STRANDEDNESS: single                                                      (D) TOPOLOGY: linear                                                 - -     (ii) MOLECULE TYPE: DNA (genomic)                                     - -     (ix) FEATURE:                                                                  (A) NAME/KEY: CDS                                                             (B) LOCATION: 95..1045                                               - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:                              - - TGCCGCCGTC CCGCCCGCCA GCGCCCCAGC GAGGAAGCAG CGCGCAGCCC GC -             #GGCCCAGC     60                                                                 - - GCACCCGCAG CAGCGCCCGC AGCTCGTCCG CGCC ATG TTC CAG G - #CG GCC GAG            112                                                                                        - #                  - #  Met Phe Gln Ala Ala Glu                             - #                  - #  1               5                  - - CGC CCC CAG GAG TGG GCC ATG GAG GGC CCC CG - #C GAC GGG CTG AAG AAG          160                                                                       Arg Pro Gln Glu Trp Ala Met Glu Gly Pro Ar - #g Asp Gly Leu Lys Lys                       10      - #            15      - #            20                   - - GAG CGG CTA CTG GAC GAC CGC CAC GAC AGC GG - #C CTG GAC TCC ATG AAA          208                                                                       Glu Arg Leu Leu Asp Asp Arg His Asp Ser Gl - #y Leu Asp Ser Met Lys                   25          - #        30          - #        35                       - - GAC GAG GAG TAC GAG CAG ATG GTC AAG GAG CT - #G CAG GAG ATC CGC CTC          256                                                                       Asp Glu Glu Tyr Glu Gln Met Val Lys Glu Le - #u Gln Glu Ile Arg Leu               40              - #    45              - #    50                           - - GAG CCG CAG GAG GTG CCG CGC GGC TCG GAG CC - #C TGG AAG CAG CAG CTC          304                                                                       Glu Pro Gln Glu Val Pro Arg Gly Ser Glu Pr - #o Trp Lys Gln Gln Leu           55                  - #60                  - #65                  - #70        - - ACC GAG GAC GGG GAC TCG TTC CTG CAC TTG GC - #C ATC ATC CAT GAA GAA          352                                                                       Thr Glu Asp Gly Asp Ser Phe Leu His Leu Al - #a Ile Ile His Glu Glu                           75  - #                80  - #                85               - - AAG GCA CTG ACC ATG GAA GTG ATC CGC CAG GT - #G AAG GGA GAC CTG GCC          400                                                                       Lys Ala Leu Thr Met Glu Val Ile Arg Gln Va - #l Lys Gly Asp Leu Ala                       90      - #            95      - #            100                  - - TTC CTC AAC TTC CAG AAC AAC CTG CAG CAG AC - #T CCA CTC CAC TTG GCT          448                                                                       Phe Leu Asn Phe Gln Asn Asn Leu Gln Gln Th - #r Pro Leu His Leu Ala                   105          - #       110          - #       115                      - - GTG ATC ACC AAC CAG CCA GAA ATT GCT GAG GC - #A CTT CTG GGA GCT GGC          496                                                                       Val Ile Thr Asn Gln Pro Glu Ile Ala Glu Al - #a Leu Leu Gly Ala Gly               120              - #   125              - #   130                          - - TGT GAT CCT GAG CTC CGA GAC TTT CGA GGA AA - #T ACC CCC CTA CAC CTT          544                                                                       Cys Asp Pro Glu Leu Arg Asp Phe Arg Gly As - #n Thr Pro Leu His Leu           135                 1 - #40                 1 - #45                 1 -      #50                                                                              - - GCC TGT GAG CAG GGC TGC CTG GCC AGC GTG GG - #A GTC CTG ACT CAG        TCC      592                                                                    Ala Cys Glu Gln Gly Cys Leu Ala Ser Val Gl - #y Val Leu Thr Gln Ser                          155  - #               160  - #               165              - - TGC ACC ACC CCG CAC CTC CAC TCC ATC CTG AA - #G GCT ACC AAC TAC AAT          640                                                                       Cys Thr Thr Pro His Leu His Ser Ile Leu Ly - #s Ala Thr Asn Tyr Asn                       170      - #           175      - #           180                  - - GGC CAC ACG TGT CTA CAC TTA GCC TCT ATC CA - #T GGC TAC CTG GGC ATC          688                                                                       Gly His Thr Cys Leu His Leu Ala Ser Ile Hi - #s Gly Tyr Leu Gly Ile                   185          - #       190          - #       195                      - - GTG GAG CTT TTG GTG TCC TTG GGT GCT GAT GT - #C AAT GCT CAG GAG CCC          736                                                                       Val Glu Leu Leu Val Ser Leu Gly Ala Asp Va - #l Asn Ala Gln Glu Pro               200              - #   205              - #   210                          - - TGT AAT GGC CGG ACT GCC CTT CAC CTC GCA GT - #G GAC CTG CAA AAT CCT          784                                                                       Cys Asn Gly Arg Thr Ala Leu His Leu Ala Va - #l Asp Leu Gln Asn Pro           215                 2 - #20                 2 - #25                 2 -      #30                                                                              - - GAC CTG GTG TCA CTC CTG TTG AAG TGT GGG GC - #T GAT GTC AAC AGA        GTT      832                                                                    Asp Leu Val Ser Leu Leu Leu Lys Cys Gly Al - #a Asp Val Asn Arg Val                          235  - #               240  - #               245              - - ACC TAC CAG GGC TAT TTC TCC TAC CAG CTC AC - #C TGG GGC CGC CCA AGC          880                                                                       Thr Tyr Gln Gly Tyr Phe Ser Tyr Gln Leu Th - #r Trp Gly Arg Pro Ser                       250      - #           255      - #           260                  - - ACC CGG ATA CAG CAG CAG CTG GGC CAG CTG AC - #A CTA GAA AAC CTT CAG          928                                                                       Thr Arg Ile Gln Gln Gln Leu Gly Gln Leu Th - #r Leu Glu Asn Leu Gln                   265          - #       270          - #       275                      - - ATG CTG CCA GAG AGT GAG GAT GAG GAG AGC TA - #T GAC ACA GAG TCA GAG          976                                                                       Met Leu Pro Glu Ser Glu Asp Glu Glu Ser Ty - #r Asp Thr Glu Ser Glu               280              - #   285              - #   290                          - - TTC ACG GAG TTC ACA GAG GAC GAG CTG CCC TA - #T GAT GAC TGT GTG TTT         1024                                                                       Phe Thr Glu Phe Thr Glu Asp Glu Leu Pro Ty - #r Asp Asp Cys Val Phe           295                 3 - #00                 3 - #05                 3 -      #10                                                                              - - GGA GGC CAG CGT CTG ACG TTA TGAGTGCAAA GGGGCTGAA - #A GAACATGGAC            1075                                                                      Gly Gly Gln Arg Leu Thr Leu                                                                   315                                                            - - TTGTATATTT GTACAAAAAA AAAGTTTTAT TTTTCTAAAA AAAGAAAAAA GA -             #AGAAAAAA   1135                                                                 - - TTTAAAGGGT GTACTTATAT CCACACTGCA CACTGCCTAG CCCAAAACGT CT -            #TATTGTGG   1195                                                                 - - TAGGATCAGC CCTCATTTTG TTGCTTTTGT GAACTTTTTG TAGGGGACGA GA -            #AAGATCAT   1255                                                                 - - TGAAATTCTG AGAAAACTTC TTTTAAACCT CACCTTTGTG GGGTTTTTGG AG -            #AAGGTTAT   1315                                                                 - - CAAAAATTTC ATGGAAGGAC CACATTTTAT ATTTATTGTG CTTCGAGTGA CT -            #GACCCCAG   1375                                                                 - - TGGTATCCTG TGACATGTAA CAGCCAGGAG TGTTAAGCGT TCAGTGATGT GG -            #GGTGAAAA   1435                                                                 - - GTTACTACCT GTCAAGGTTT GTGTTACCCT CCTGTAAATG GTGTACATAA TG -            #TATTGTTG   1495                                                                 - - GTAATTATTT TGGTACTTTT ATGATGTATA TTTATTAAAG AGATTTTTAC AA - #ATG            1550                                                                       - -  - - (2) INFORMATION FOR SEQ ID NO:18:                                    - -      (i) SEQUENCE CHARACTERISTICS:                                                 (A) LENGTH: 317 amino - #acids                                                (B) TYPE: amino acid                                                          (D) TOPOLOGY: linear                                                 - -     (ii) MOLECULE TYPE: protein                                           - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:                              - - Met Phe Gln Ala Ala Glu Arg Pro Gln Glu Tr - #p Ala Met Glu Gly Pro        1               5 - #                 10 - #                 15              - - Arg Asp Gly Leu Lys Lys Glu Arg Leu Leu As - #p Asp Arg His Asp Ser                   20     - #             25     - #             30                  - - Gly Leu Asp Ser Met Lys Asp Glu Glu Tyr Gl - #u Gln Met Val Lys Glu               35         - #        40          - #        45                       - - Leu Gln Glu Ile Arg Leu Glu Pro Gln Glu Va - #l Pro Arg Gly Ser Glu          50              - #    55              - #    60                           - - Pro Trp Lys Gln Gln Leu Thr Glu Asp Gly As - #p Ser Phe Leu His Leu       65                 - # 70                 - # 75                 - # 80       - - Ala Ile Ile His Glu Glu Lys Ala Leu Thr Me - #t Glu Val Ile Arg Gln                       85 - #                 90 - #                 95              - - Val Lys Gly Asp Leu Ala Phe Leu Asn Phe Gl - #n Asn Asn Leu Gln Gln                  100      - #           105      - #           110                  - - Thr Pro Leu His Leu Ala Val Ile Thr Asn Gl - #n Pro Glu Ile Ala Glu              115          - #       120          - #       125                      - - Ala Leu Leu Gly Ala Gly Cys Asp Pro Glu Le - #u Arg Asp Phe Arg Gly          130              - #   135              - #   140                          - - Asn Thr Pro Leu His Leu Ala Cys Glu Gln Gl - #y Cys Leu Ala Ser Val      145                 1 - #50                 1 - #55                 1 -      #60                                                                              - - Gly Val Leu Thr Gln Ser Cys Thr Thr Pro Hi - #s Leu His Ser Ile        Leu                                                                                             165  - #               170  - #               175             - - Lys Ala Thr Asn Tyr Asn Gly His Thr Cys Le - #u His Leu Ala Ser Ile                  180      - #           185      - #           190                  - - His Gly Tyr Leu Gly Ile Val Glu Leu Leu Va - #l Ser Leu Gly Ala Asp              195          - #       200          - #       205                      - - Val Asn Ala Gln Glu Pro Cys Asn Gly Arg Th - #r Ala Leu His Leu Ala          210              - #   215              - #   220                          - - Val Asp Leu Gln Asn Pro Asp Leu Val Ser Le - #u Leu Leu Lys Cys Gly      225                 2 - #30                 2 - #35                 2 -      #40                                                                              - - Ala Asp Val Asn Arg Val Thr Tyr Gln Gly Ty - #r Phe Ser Tyr Gln        Leu                                                                                             245  - #               250  - #               255             - - Thr Trp Gly Arg Pro Ser Thr Arg Ile Gln Gl - #n Gln Leu Gly Gln Leu                  260      - #           265      - #           270                  - - Thr Leu Glu Asn Leu Gln Met Leu Pro Glu Se - #r Glu Asp Glu Glu Ser              275          - #       280          - #       285                      - - Tyr Asp Thr Glu Ser Glu Phe Thr Glu Phe Th - #r Glu Asp Glu Leu Pro          290              - #   295              - #   300                          - - Tyr Asp Asp Cys Val Phe Gly Gly Gln Arg Le - #u Thr Leu                  305                 3 - #10                 3 - #15                          __________________________________________________________________________

We claim:
 1. A method for identifying a chemical as a potentialmedicament for increasing gene expression, comprising the steps of:a)expressing a nucleic acid encoding an IκB protein having the sequenceset forth as SEQ ID NO:18; b) preparing a complex comprising said IκBprotein and an NF-κB protein and contacting the complex with saidchemical; and c) identifying said chemical as a potential medicament forincreasing gene expression by its capacity to dissociate the complex ofstep b).
 2. The method according to claim 1 wherein said nucleic acidcomprises nucleotides 95-1045 of SEQ ID NO:17.
 3. The method accordingto claim 2 wherein said nucleic acid comprises the sequence set forth asSEQ ID NO:17.
 4. A method for identifying a chemical as a potentialmedicament for decreasing gene expression, comprising the steps of:a)expressing a nucleic acid encoding an IκB protein having the sequenceset forth as SEQ ID NO:18; b) preparing a complex comprising said IκBprotein and an NF-κB protein and contacting the complex with saidchemical; and c) identifying said chemical as a potential medicament fordecreasing gene expression by its capacity to prevent or retard thedissociation of said IκB protein from the complex of step b).
 5. Themethod according to claim 4 wherein said nucleic acid comprisesnucleotides 95-1045 of SEQ ID NO:17.
 6. The method according to claim 5wherein said nucleic acid comprises the sequence set forth as SEQ IDNO:17.